HBM Healthcare Investments — 2020 Investments
2 investments dated 2020 · listed companies and verified rows first · show all
Biohaven is a biopharmaceutical company that discovers, develops, and commercializes treatments across immunology, obesity, neuroscience, and oncology, targeting rare and common diseases with limited treatment options.
BiotechHealthtech
Vlad Coric(Chairman & Chief Executive Officer)in
Co-investorsAisling CapitalAPERTURE Venture PartnersConnecticut InnovationsOUP (Osage University Partners)OrbiMed
Dren Bio is a clinical-stage biopharmaceutical company developing novel antibody therapeutics designed to selectively eliminate pathogenic cells and disease-causing agents, with a pipeline targeting oncology, autoimmune diseases, immunology, and neurology.
BiotechHealthtechMedical DevicesFoster City, US
Nenad Tomasevic(Chief Executive Officer, Founder)
BoardIvan Trifunovich(Director)John Wesley(Director)
Co-investors8VCAisling CapitalMission Bay CapitalMission BiocapitalOlive Tree CapitalSR One Capital Management+3 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.